Lv1
40 积分 2025-09-14 加入
Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study
1个月前
已完结
The TNFRSF members CD27 and OX40 coordinately limit TH17 differentiation in regulatory T cells
1个月前
已完结
Inflammatory memory in psoriasis: From remission to recurrence
2个月前
已完结
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
2个月前
已完结
Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019
2个月前
已完结
皖公网安备34019202002308
